Zometa

Country of origin: Switzerland
Pharm-Group: Various anti-osteoporosis agents

Manufacturers: Novartis Pharma AG (Switzerland)
International name: Zoledronic acid
Dosage forms: powder for injection solution 4 mg
Composition: Active substance - zoledronic acid.

Indications for use: Osteolytic, osteoblastic and mixed bone metastases of solid tumors and osteolytic lesions in multiple myeloma, as part of combination therapy; hypercalcemia caused by a malignant tumor.

Contraindications: Hypersensitivity, pregnancy, lactation.

Side effects: Headache, weakness, paresthesia, impaired taste, hypoesthesia, hyperesthesia, tremor; thrombocytopenia, anemia, leukopenia; pancytopenia; anxiety, sleep disorders, confusion; conjunctivitis, blurred vision; nausea, vomiting, anorexia, diarrhea, constipation, abdominal pain, dyspepsia, stomatitis, dry mouth; dyspnea, cough; itching, rash, increased sweating; bone pain, myalgia, arthralgia, muscle cramps; bradycardia; impaired renal function, acute renal failure, hematuria, proteinuria; hypersensitivity reactions, angioedema; fever, flu-like syndrome, manifested by fever, chills, bone and/or muscle pain, asthenia, peripheral edema, chest pain, weight gain; pain, irritation, swelling and infiltration at the injection site; hypophosphatemia, increased levels of creatinine and urea in the blood serum, hypocalcemia, hypomagnesemia, hyperkalemia, hypokalemia, hypernatremia.

Interaction: Caution is recommended when using bisphosphonates and aminoglycosides simultaneously. Use caution when prescribing with drugs that have potential nephrotoxic effects. A diluted Zometa solution should not be mixed with infusion solutions containing calcium ions.

Overdose: In case of hypocalcemia with clinically significant manifestations, an infusion of calcium gluconate is indicated.

Special instructions: Prescribing the drug to patients with severely impaired renal function is not recommended, except in cases where the expected benefit outweighs the potential risk. Before infusion, the patient should be excluded from dehydration. After administration of the drug, constant monitoring of the concentration of calcium, phosphorus, magnesium and creatinine in the blood serum is necessary. The effectiveness and safety of Zometa in pediatric practice have not yet been established.

Literature: Vidal reference book, 2006.